Hyunseok Kang
Hematology & Oncology · Palo Alto, CANPI 1316108509
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Bayer at 40.2% of the total. Reporting peaked in 2022 at $17,793 and has fallen 75.9% since, to $4,294 in 2024.
Across 54 payments — averaging $1027.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$22K
- Coherus Oncology, Inc.$10K
- Exelixis Inc.$9K
- Eli Lilly$7K
- F. Hoffmann-la Roche AG$3K
- GSK$3K
- plus $1K from 10 others
Across 20 payments — averaging $82,820 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.3M
- Merck$328K
- Exelixis Inc.$30K
What the payments were for
- Consulting fees$27,76150%
- Speaking & faculty fees$15,66028%
- Travel & lodging$10,68919%
- Food & beverage$1,3672%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 12 | $22,298 |
| Coherus Oncology, Inc. | 6 | $9,857 |
| Exelixis Inc. | 12 | $8,638 |
| Eli Lilly | 8 | $7,458 |
| F. Hoffmann-la Roche AG | 2 | $3,132 |
| GSK | 3 | $3,103 |
| AstraZeneca | 1 | $238 |
| Genentech USA, Inc. | 2 | $212 |
| Sanofi | 1 | $200 |
| Regeneron Healthcare Solutions, Inc. | 1 | $132 |
| Pfizer | 1 | $74 |
| Puma Biotechnology, Inc. | 1 | $60 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $40 |
| Illumina, Inc. | 1 | $31 |
| Gilead | 1 | $12 |
| Genentech, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,487 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 19 | $436,205 |
| MekinistTrametinib Dimethyl Sulfoxide | 20 | $256,477 |
| TafinlarDabrafenib Mesylate | 15 | $171,302 |
| RetevmoSelpercatinib | 12 | $169,313 |
| Ondansetron Hcl | 37 | $637 |
| Dexamethasone | 12 | $320 |
| Prochlorperazine Maleate | 28 | $250 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Palo Alto
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.